Filing Details
- Accession Number:
- 0001209191-20-016416
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-03-04 20:33:32
- Reporting Period:
- 2020-03-02
- Accepted Time:
- 2020-03-04 20:33:32
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1503802 | Karyopharm Therapeutics Inc. | KPTI | Pharmaceutical Preparations (2834) | 263931704 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1603510 | Brett Christopher Primiano | C/O Karyopharm Therapeutics Inc. 85 Wells Avenue Newton MA 02459 | Evp, Cbo, Gc & Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-03-02 | 26,500 | $10.39 | 36,867 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-03-02 | 7,500 | $23.50 | 29,367 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-03-02 | 10,000 | $28.00 | 19,367 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-03-02 | 9,000 | $24.00 | 10,367 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2020-03-02 | 26,500 | $0.00 | 26,500 | $10.39 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 76,500 | 2027-01-19 | No | 4 | M | Direct |
Footnotes
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.04, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
